The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set
Open accessAbstract
The primary cause of morbidity and mortality in patients with multiple myeloma (MM) is an infection. Therefore, there is great concern about susceptibility to the outcome of COVID-19–infected patients with MM. This retrospective study describes the baseline characteristics and outcome data of COVID-19 infection in 650 patients with plasma cell disorders, collected by the International Myeloma Society to understand the initial challenges faced by myeloma patients during the COVID-19 pandemic. Analyses were performed for hospitalized MM patients. Among hospitalized patients, the median age was 69 years, and nearly all patients (96%) had MM. Approximately 36% were recently diagnosed (2019-2020), and 54% of patients were receiving first-line therapy. Thirty-three percent of patients have died, with significant geographic variability, ranging from 27% to 57% of hospitalized patients. Univariate analysis identified age, International Staging System stage 3 (ISS3), high-risk disease, renal disease, suboptimal myeloma control (active or progressive disease), and 1 or more comorbidities as risk factors for higher rates of death. Neither history of transplant, including within a year of COVID-19 diagnosis, nor other anti-MM treatments were associated with outcomes. Multivariate analysis found that only age, high-risk MM, renal disease, and suboptimal MM control remained independent predictors of adverse outcome with COVID-19 infection. The management of MM in the era of COVID-19 requires careful consideration of patient- and disease-related factors to decrease the risk of acquiring COVID-19 infection, while not compromising disease control through appropriate MM treatment. This study provides initial data to develop recommendations for the management of MM patients with COVID-19 infection.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy
Onder, G., Rezza, G., & Brusaferro, S. (2020) · JAMA · doi:10.1001/jama.2020.4683 · Cited by 4,171
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
Kuderer, N. M., Choueiri, T. K., Shah, D. P., Shyr, Y., Rubinstein, S. M., Rivera, D. R., Shete, S., Hsu, C.-Y., Desai, A., de Lima Lopes, G., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31187-9 · Cited by 1,726
Lee, L. Y., Cazier, J.-B., Angelis, V., Arnold, R., Bisht, V., Campton, N. A., Chackathayil, J., Cheng, V. W., Curley, H. M., Fittall, M. W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31173-9 · Cited by 1,103
Estimating the burden of SARS-CoV-2 in France
Salje, H., Tran Kiem, C., Lefrancq, N., Courtejoie, N., Bosetti, P., Paireau, J., Andronico, A., Hozé, N., Richet, J., Dubost, C.-L., et al. (2020) · Science · doi:10.1126/science.abc3517 · Cited by 1,038
Cited by
CD8+ T cells contribute to survival in patients with COVID-19 and hematologic cancer
Bange, E. M., Han, N. A., Wileyto, P., Kim, J. Y., Gouma, S., Robinson, J., Greenplate, A. R., Hwee, M. A., Porterfield, F., Owoyemi, O., et al. (2021) · Nature Medicine · doi:10.1038/s41591-021-01386-7 · Cited by 519
Pagano, L., Salmanton-García, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01177-0 · Cited by 315
Grivas, P., Khaki, A. R., Wise-Draper, T. M., French, B., Hennessy, C., Hsu, C.-Y., Shyr, Y., Li, X., Choueiri, T. K., Painter, C. A., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.02.024 · Cited by 309
Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00879-7 · Cited by 209
Self-citationNeutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
Terpos, E., Rajkumar, S. V., & Leung, N. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2021.5942 · Cited by 22
Metadata
- Authors
- Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K., Hungria, V., Engelhardt, M., Gay, F., García Feria, A., Oliva, S., Oostvogels, R., Gozzetti, A., Rosenbaum, C., Kumar, S., Stadtmauer, E. A., Einsele, H., Beksac, M., Weisel, K., Anderson, K. C., Mateos, M.-V., Moreau, P., San-Miguel, J., Munshi, N. C., & Avet-Loiseau, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2020-12-24
- Volume
- 136
- Issue
- 26
- Pages
- 3033-3040
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W3096680486
- Cited by
- 187
- References
- 4
- FWCI
- 20.79
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. https://app.cochat.ai/papers/10.1182/blood.2020008150
- The paper
- Chari, A., Samur, M. K., Martinez-Lopez, J., Cook, G., Biran, N., Yong, K., Hungria, V., Engelhardt, M., Gay, F., García Feria, A., Oliva, S., Oostvogels, R., Gozzetti, A., Rosenbaum, C., Kumar, S., Stadtmauer, E. A., Einsele, H., Beksac, M., Weisel, K., . . . Avet-Loiseau, H. (2020). Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. https://doi.org/10.1182/blood.2020008150
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.